BioMarin [BMRN] vs Royalty Pharma plc [RPRX] Detailed Stock Comparison
BioMarin
NASDAQ
Loading...
Royalty Pharma plc
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: BioMarin wins in 9 metrics, Royalty Pharma plc wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | BioMarin | Royalty Pharma plc | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 17.13 | 15.65 | Royalty Pharma plc |
| Price-to-Book Ratio | 1.85 | 2.44 | BioMarin |
| Debt-to-Equity Ratio | 10.02 | 84.43 | BioMarin |
| PEG Ratio | 0.14 | -0.22 | Royalty Pharma plc |
| EV/EBITDA | 10.81 | 19.05 | BioMarin |
| Profit Margin (TTM) | 21.45% | 44.28% | Royalty Pharma plc |
| Operating Margin (TTM) | 33.55% | 38.85% | Royalty Pharma plc |
| EBITDA Margin (TTM) | 33.55% | 38.85% | Royalty Pharma plc |
| Return on Equity | 11.62% | 17.29% | Royalty Pharma plc |
| Return on Assets (TTM) | 7.50% | 6.49% | BioMarin |
| Free Cash Flow (TTM) | $475.42M | $2.77B | Royalty Pharma plc |
| Dividend Yield | N/A | 3.03% | N/A |
| 1-Year Return | -34.96% | 28.84% | Royalty Pharma plc |
| Price-to-Sales Ratio (TTM) | 3.64 | 9.06 | BioMarin |
| Enterprise Value | $10.32B | $26.06B | Royalty Pharma plc |
| EV/Revenue Ratio | 3.37 | 11.31 | BioMarin |
| Gross Profit Margin (TTM) | 81.82% | N/A | N/A |
| Revenue per Share (TTM) | $16 | $5 | BioMarin |
| Earnings per Share (Diluted) | $3.39 | $2.29 | BioMarin |
| Beta (Stock Volatility) | 0.18 | 0.54 | BioMarin |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
BioMarin vs Royalty Pharma plc Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| BioMarin | 0.88% | 1.81% | -1.05% | 0.98% | -15.11% | -11.90% |
| Royalty Pharma plc | 0.08% | -0.03% | 0.66% | 12.47% | 7.51% | 40.91% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| BioMarin | -34.96% | -35.67% | -23.34% | -56.04% | 181.90% | 648.72% |
| Royalty Pharma plc | 28.84% | -15.63% | -13.67% | -25.88% | -25.88% | -25.88% |
Performance & Financial Health Analysis: BioMarin vs Royalty Pharma plc
| Metric | BMRN | RPRX |
|---|---|---|
| Market Information | ||
| Market Cap | $11.15B | $20.90B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 2,021,330 | 3,182,093 |
| 90 Day Avg. Volume | 2,212,803 | 2,715,521 |
| Last Close | $58.58 | $36.34 |
| 52 Week Range | $52.93 - $93.04 | $24.05 - $38.00 |
| % from 52W High | -37.04% | -4.37% |
| All-Time High | $151.75 (Jul 20, 2015) | $56.50 (Jun 15, 2020) |
| % from All-Time High | -61.40% | -35.68% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.16% | 0.08% |
| Quarterly Earnings Growth | 1.24% | -0.70% |
| Financial Health | ||
| Profit Margin (TTM) | 0.21% | 0.44% |
| Operating Margin (TTM) | 0.34% | 0.39% |
| Return on Equity (TTM) | 0.12% | 0.17% |
| Debt to Equity (MRQ) | 10.02 | 84.43 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $31.39 | $14.68 |
| Cash per Share (MRQ) | $7.46 | $1.49 |
| Operating Cash Flow (TTM) | $766.77M | $2.41B |
| Levered Free Cash Flow (TTM) | $503.09M | $-746,665,024 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 3.03% |
| Last 12-Month Dividend | N/A | $1.08 |
Valuation & Enterprise Metrics Analysis: BioMarin vs Royalty Pharma plc
| Metric | BMRN | RPRX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 17.13 | 15.65 |
| Forward P/E | 19.42 | 8.16 |
| PEG Ratio | 0.14 | -0.22 |
| Price to Sales (TTM) | 3.64 | 9.06 |
| Price to Book (MRQ) | 1.85 | 2.44 |
| Market Capitalization | ||
| Market Capitalization | $11.15B | $20.90B |
| Enterprise Value | $10.32B | $26.06B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.37 | 11.31 |
| Enterprise to EBITDA | 10.81 | 19.05 |
| Risk & Other Metrics | ||
| Beta | 0.18 | 0.54 |
| Book Value per Share (MRQ) | $31.39 | $14.68 |
Financial Statements Comparison: BioMarin vs Royalty Pharma plc
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BMRN | RPRX |
|---|---|---|
| Revenue/Sales | $825.41M | $578.67M |
| Cost of Goods Sold | $150.09M | N/A |
| Gross Profit | $675.32M | N/A |
| Research & Development | $161.31M | $300.50M |
| Operating Income (EBIT) | $276.87M | $209.80M |
| EBITDA | $319.11M | $219.28M |
| Pre-Tax Income | $297.87M | $90.64M |
| Income Tax | $57.34M | $0 |
| Net Income (Profit) | $240.53M | $90.64M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BMRN | RPRX |
|---|---|---|
| Cash & Equivalents | $1.05B | $1.09B |
| Total Current Assets | $3.47B | $1.84B |
| Total Current Liabilities | $628.21M | $1.18B |
| Long-Term Debt | $595.65M | $6.62B |
| Total Shareholders Equity | $5.79B | $9.79B |
| Retained Earnings | $-9.01M | $2.48B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BMRN | RPRX |
|---|---|---|
| Operating Cash Flow | $182.82M | $1.28B |
| Capital Expenditures | $-16.77M | N/A |
| Free Cash Flow | $157.63M | $596.08M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-708.78M |
Short Interest & Institutional Ownership Analysis
| Metric | BMRN | RPRX |
|---|---|---|
| Shares Short | 5.15M | 15.18M |
| Short Ratio | 2.84 | 5.25 |
| Short % of Float | 0.03% | 0.04% |
| Average Daily Volume (10 Day) | 2,021,330 | 3,182,093 |
| Average Daily Volume (90 Day) | 2,212,803 | 2,715,521 |
| Shares Outstanding | 190.76M | 445.99M |
| Float Shares | 178.10M | 379.85M |
| % Held by Insiders | 0.01% | 0.09% |
| % Held by Institutions | 0.99% | 0.85% |
Dividend Analysis & Yield Comparison: BioMarin vs Royalty Pharma plc
| Metric | BMRN | RPRX |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.08 |
| Last 12-Month Dividend Yield | N/A | 3.03% |
| 3-Year Avg Annual Dividend | N/A | $0.89 |
| 3-Year Avg Dividend Yield | N/A | 0.64% |
| 3-Year Total Dividends | N/A | $2.68 |
| Ex-Dividend Date | N/A | Aug 15, 2025 |